Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus.
10.4093/dmj.2016.40.3.240
- Author:
Sejeong PARK
1
;
So Young PARK
;
Yu Jin KIM
;
Soo Min HONG
;
Suk CHON
;
Seungjoon OH
;
Jeong taek WOO
;
Sung Woon KIM
;
Young Seol KIM
;
Sang Youl RHEE
Author Information
1. Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. bard95@hanmail.net
- Publication Type:Original Article
- Keywords:
Diabetes mellitus, type 2;
Gastrointestinal diseases;
Rebamipide
- MeSH:
Abdominal Pain;
Constipation;
Diabetes Mellitus, Type 2*;
Diarrhea;
Dyspepsia;
Gastrointestinal Diseases;
Hemoglobin A, Glycosylated;
Humans;
Irritable Bowel Syndrome;
Male;
Nausea;
Peptic Ulcer;
Vomiting
- From:Diabetes & Metabolism Journal
2016;40(3):240-247
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM. METHODS: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms. RESULTS: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study. CONCLUSION: Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.
